Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Has Consensus Price Target of $13.08 According to Brokerages

Key Points

• Analysts maintain a consensus “Hold” rating on Vanda Pharmaceuticals, with six buys, one hold, and two sells. The average 12-month price target is $13.08, although individual targets range from $10 to $20.
• Vanda’s shares opened at $3.94, near their 12-month low of $3.88, and have declined below both their 50-day ($4.91) and 200-day ($6.29) moving averages.
• The company reported weaker-than-expected quarterly results, including an EPS loss of $1.04 versus a projected loss of $0.58 and revenue of $50.53 million versus estimates of $61.92 million. Institutional investors own 88.14% of the stock.

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA - Get Free Report) have been given a consensus rating of "Hold" by the nine analysts that are covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $13.08.

Several equities analysts have recently weighed in on the stock. Oppenheimer assumed coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They set an "outperform" rating and a $10.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Zacks Research lowered shares of Vanda Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 6th. B. Riley Financial reaffirmed a "buy" rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Finally, HC Wainwright reissued a "buy" rating and set a $20.00 price objective on shares of Vanda Pharmaceuticals in a research note on Monday, October 5th.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. purchased a new stake in shares of Vanda Pharmaceuticals in the second quarter worth approximately $46,841,000. AIGH Capital Management LLC purchased a new position in Vanda Pharmaceuticals during the second quarter valued at approximately $12,510,000. State Street Corp grew its position in Vanda Pharmaceuticals by 16.6% during the second quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company's stock valued at $21,520,000 after purchasing an additional 500,843 shares in the last quarter. Renaissance Technologies LLC increased its stake in Vanda Pharmaceuticals by 11.2% in the 1st quarter. Renaissance Technologies LLC now owns 3,759,559 shares of the biopharmaceutical company's stock valued at $25,979,000 after buying an additional 378,598 shares during the period. Finally, Ieq Capital LLC acquired a new position in Vanda Pharmaceuticals in the 2nd quarter valued at approximately $1,731,000. 88.14% of the stock is owned by hedge funds and other institutional investors.

Vanda Pharmaceuticals Stock Down 1.7%

VNDA opened at $3.94 on Tuesday. The stock's 50 day moving average price is $4.91 and its 200 day moving average price is $6.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.61 and a quick ratio of 1.60. The stock has a market cap of $238.21 million, a P/E ratio of -0.85 and a beta of 0.69. Vanda Pharmaceuticals has a 12 month low of $3.88 and a 12 month high of $9.94.

Vanda Pharmaceuticals (NASDAQ:VNDA - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.46). The business had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative return on equity of 49.81% and a negative net margin of 127.41%. As a group, research analysts predict that Vanda Pharmaceuticals will post -3.02 earnings per share for the current year.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda's marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.